Form 4: Day One Biopharmaceuticals Executive Samuel Blackman Sells 30,000 Shares

Samuel Blackman, Head of R&D at Day One Biopharmaceuticals, sold 30,000 shares of common stock at an average price of $12.6196 on June 10, 2024, according to a Form 4 filing.

Summary

• On June 10, 2024, Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 30,000 shares of the company's common stock.
• The shares were sold at a weighted average price of $12.6196, with individual prices ranging from $12.47 to $12.79.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2023.
• Following the transaction, Blackman directly owns 1,141,081 shares of Day One Biopharmaceuticals.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider stock sale. The sentiment is neutral as it simply reports a transaction without expressing any opinion on the company's performance or future prospects.

Industry Context

Insider sales are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. A pre-planned sale under Rule 10b5-1 suggests the sale was scheduled in advance to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates